ABclonal Funding: $282M Raised, Series D (2021)

ABclonal funding overview

ABclonal is based in Woburn. ABclonal has raised $282M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in December 2021. The round record for ABclonal runs through 2021; nothing later has been disclosed. Investors on record include CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management. 5 distinct backers are named across the disclosed rounds.

ABclonal at a glance

Total raised: $282M
Latest round: Series D
Latest round date: December 2021
Headquarters: Woburn
Notable investors: CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management

Frequently asked about ABclonal funding

How much has ABclonal raised?: ABclonal has raised $282M in total disclosed funding across the rounds on record.
Who has invested in ABclonal?: CMB International Capital, HongShan, Lucion Venture Capital Group, Loyal Valley Capital, Taikang Asset Management are named among the investors backing ABclonal.
What was the latest ABclonal funding round?: The most recent disclosed round is a Series D, announced in December 2021.
Where is ABclonal based?: ABclonal is based in Woburn.
When did ABclonal last raise?: The last disclosed ABclonal round closed in December 2021 at Series D.

ABclonal totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Woburn below to benchmark round size and investor mix.

ABclonal Funding: $282M Raised, Series D (2021)

ABclonal funding overview

ABclonal at a glance

Frequently asked about ABclonal funding

Companies related to ABclonal (22)

Browse related funding lists (4)